All stock lists
Evolus, Inc. (NASDAQ:EOLS)
US · Delayed Price · Currency is USD
Also listed: 0K16.LHealthcare · Drug Manufacturers - Specialty & Generic
7.14+0.14 (+1.93%)
Insider Score
––Not scored
EOLS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
EOLS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 84.08 M | 73.14 M | 90.30 M | 68.97 M | 69.39 M | 68.52 M |
| Revenue Growth (YoY) | 21.18 % | 6.74 % | 14.38 % | 12.90 % | 3.70 % | 15.49 % |
| Cost of Revenue | 26.90 M | 25.78 M | 31.01 M | 23.13 M | 24.07 M | 21.87 M |
| Gross Profit | 57.18 M | 47.36 M | 59.29 M | 45.84 M | 45.32 M | 46.66 M |
| SG&A Expense | 57.05 M | 51.98 M | 54.66 M | 52.82 M | 56.67 M | 56.64 M |
| R&D Expense | 1.89 M | 2.24 M | 3.48 M | 2.05 M | 1.84 M | 2.21 M |
| Operating Expenses | 61.72 M | 54.22 M | 59.58 M | 57.34 M | 55.53 M | 61.83 M |
| Operating Income | -4.54 M | -6.86 M | -291.00 K | -11.50 M | -10.21 M | -15.17 M |
| Pretax Income | -8.21 M | -10.42 M | 515.00 K | -15.57 M | -17.09 M | -18.82 M |
| Tax Provision | -154.00 K | 256.00 K | 385.00 K | 167.00 K | 53.00 K | 72.00 K |
| Net Income | -8.05 M | -10.67 M | 130.00 K | -15.74 M | -17.14 M | -18.89 M |
| EPS (Basic) | -0.12 | -0.16 | 0.00 | -0.24 | -0.27 | -0.30 |
| EPS (Diluted) | -0.12 | -0.16 | 0.00 | -0.24 | -0.27 | -0.30 |
| Shares Outstanding | 65.93 M | 65.19 M | 64.47 M | 64.73 M | 64.54 M | 63.70 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.